Anti-invasive and Antimetastatic Activities of Ribosomal Protein S6 Kinase 4 in Breast Cancer Cells

Archana Thakur, Yuan Sun, Alicia Bollig, Jack Wu, Hector Biliran, Sanjeev Banerjee, Fazlul H. Sarkar, and D. Joshua Liao

Abstract

Purpose: We have previously shown that p90 ribosomal protein S6 kinase 4 (RSK4), an X-linked gene, is highly up-regulated in mammary tumors of MMTV-c-Myc transgenic mice. In this study, we further investigated whether RSK4 inhibits or promotes breast tumor growth and progression.

Experimental Design: Stable overexpression or small interfering RNA–mediated knockdown of RSK4 was done in the MDA-MB-231 cell line. Stable clones were tested for cell proliferation, anchorage-independent growth in soft agar, invasive and metastatic ability of these clones in vitro and tumorigenesis, invasive and metastatic ability in vivo in severe combined immunodeficient mice.

Results: Here, we show that exogenous expression of RSK4 resulted in decreased cell proliferation and increased accumulation of cells in G0-G1 phase, which paralleled with enhanced expression of tumor suppressor genes: retinoblastoma protein, retinoblastoma-associated 46 kDa protein, and p21 protein. Overexpression of RSK4 resulted in reduced colony formation in soft agar and suppressed invasive and migratory activities of MDA-MB-231 cells both in vitro and in vivo. Importantly, RSK4-overexpressing cells showed up-regulation of claudin-2 and down-regulation of CXCR4, both of these play roles in invasion and chemotaxis.

Conclusions: These results indicate that RSK4 expression may limit the oncogenic, invasive, and metastatic potential of breast cancer cells. Anti-invasive and antimetastatic activities of RSK4 may be, in part, due to its regulation of claudin-2. Increased expression of RSK4 in c-Myc-overexpressing cells and a dose-dependent induction of luciferase reporter gene activity suggest that c-Myc may regulate RSK4 expression.

Breast cancer still remains one of the most common malignancies and a major cause of cancer-related deaths among women in the United States. The main cause of cancer-related death is due to the progression of noninvasive solid tumor to invasive and metastatic phenotype, yet the mechanisms underlying the progression of noninvasive to fatal metastatic breast cancer remain unclear. Tumor progression from noninvasive to metastatic results from a multitude of genetic events. Identification of molecules or endogenous factor(s) that play a role in the process of cancer progression from noninvasive to invasive and metastatic will allow development of new therapeutic approaches to prevent or treat metastatic breast cancer.

In our search for c-Myc target X-linked genes, we showed previously a significant up-regulation of ribosomal protein S6 kinase 4 (RSK4) mRNA in mammary tumors of MMTV-c-Myc transgenic mice compared with normal mammary glands (1). RSK4, an intracellular serine/threonine kinase, belongs to p90 ribosomal S6 kinase (RSK) family of related kinases that includes both activating and inhibitory isoforms and signals downstream of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase pathway (2–4). RSK family members RSK1, RSK2, and RSK3 are the central mediators of extracellular signal-regulated kinase in the regulation of survival, growth, proliferation, invasion, and metastasis via phosphorylation of numerous intracellular proteins including several transcription factors and coregulators such as CREB, CBP, p300, IκBα, c-fos, and ERF (5–12). RSK4 is constitutively activated in serum-starved cells and shown to suppress cell proliferation as opposed to growth factor–dependent RSK1, RSK2, and RSK3 (13). Depletion of RSK4 bypassed the p53-dependent G1 cell cycle arrest (14) and strongly suppressed mRNA expression of cyclin-dependent kinase inhibitor p21^{CIP1} (p21). In another study, Myers et al. showed that RSK4 expression disrupted mesoderm formation induced by the fibroblast growth factor-Ras-extracellular signal-regulated kinase signaling pathway (15). Together, these studies suggest that RSK4 is distinct from RSK1-3 and appears to have growth-inhibitory function. Interestingly, we observed that RSK4-overexpressing mammary tumors of MMTV-c-Myc transgenic mice are noninvasive and do not metastasize, suggesting that...
noninvasive and nonmetastatic properties of these tumors may be attributed by RSK4. Moreover, weak to moderate expression of RSK4 protein in human invasive ductal carcinoma and strong positive staining in ductal carcinoma in situ may further suggest its anti-invasive and antitumor metastatic in breast cancer (16). Based on our and other previous studies and our observation, we hypothesized that increased expression of RSK4 may restrict tumor growth and suppress mammary tumor invasion and metastasis. Our results indicate that RSK4 can suppress tumorigenic phenotype and may play a critical role in invasion and migration of breast cancer cells.

Materials and Methods

Cell lines, plasmids, and transfection
The human breast cancer cell lines, MDA-MB-231 and T47D, were cultured in DMEM/F-12 or RPMI 1640 (Invitrogen), respectively, with 10% fetal bovine serum (FBS; Invitrogen) at 37°C and 5% CO2. The human MDA-MB-231, a highly invasive and metastatic cell line, was chosen to generate the RSK4-overexpressing stable clones because it showed lower levels of endogenous RSK4. The RSK4 construct (pMT2-HA-RSK4) was kindly provided by Dr. Frodin Morten (Kinesin Signaling Laboratory, Biotech Research and Innovation Centre). The RSK4 (GenBank accession no. NM_014496) insert, which encodes the entire RSK4 protein, was subcloned in pcDNA3.1/Neo(-) vector for stable transfection. The pBabe-Puro-MycER expression vector contained the mutant hormone-binding domain of the murine estrogen receptor (which retains the ability to bind 4-hydroxytamoxifen but not estrogen) fused at the COOH terminus of the human c-Myc protein (amino acids 1-435) to form c-MycER (14). The pcDNA3.1/Neo-RSK4 or pBabe-Puro-MycER plasmids were used to stably transfect the MDA-MB-231 or T47D cell lines to overexpress the human RSK4 or c-Myc gene. Transfection was done using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Briefly, MDA-MB-231 or T47D cells were cultured in six-well plates at 80% to 90% confluency. Plasmid DNA (1.0 µg/well) was mixed with 10 µL LipofectAamine 2000 and transfected into the MDA-MB-231 or T47D cells. After 48 h, cells were trypsinized and replated into 10-cm culture dishes in the presence of 800 µg/mL neomycin or 2.5 µg/mL puromycin. Single-cell clones were isolated for transfection. One cell clone was screened by reverse transcription-PCR and Western blot to determine the RSK4 expression at both mRNA and protein levels. Stable clones were cultured and maintained (400 µg/mL neomycin and 1 µg/mL puromycin) at least 15 passages before using them for various experiments.

RNA extraction and reverse transcription-PCR
Total RNA was extracted from transfected cells using RNeasy (Qiagen) spin columns according to the manufacturer’s instructions and stored at -80°C until use. Exogenous RSK4 was identified by reverse transcription-PCR using Taqman RT kit (Applied Biosystems) and Ready PCR Mix (Sigma) in stably transfected clones. Transfected RSK4 was identified using the upstream primer located in the vector (BGH: 5’-TAGAAAGGCACAGTCGAGG-3’) and downstream primer located in RSK4 insert (5’TCCCCAGTTCACACCTCAGAAA-3’). For the detection of RSK4 mRNA expression, the upstream primer was replaced with 5’-GGAAAGGAGGGCTACTAGTATA-3’ and downstream control primers of pCDNA3.1-neo were identified by using T7 and BGH primer pairs (T7: 5’TATAACAGCCTACATAGG-3’ and BGH: 5’TAGAAAGGCA-CATCGAGG-3’).

Immunoblotting

For immunoblotting, cells were washed twice with ice-cold PBS and lysed in radioimmunoprecipitation assay buffer (50 mmol/L Tris-HCl, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L DTT, 0.1% Tween 20, 1 mmol/L phenylmethylsulfonyl fluoride, 10 mmol/L β-glycerophosphate, 1 mmol/L NaF, 2 mmol/L Na3VO4, 1.5 µg/mL leupeptin, and 1-5 µg/mL aprotinin). Nuclear extract was prepared by using nuclear extraction buffer as described previously (17). Protein was quantitated using a BCA protein assay (Pierce). Protein aliquots (50 µg/ lane) or 25 µL immunoprecipitated samples were separated on SDS-PAGE and transferred onto a nitrocellulose membrane for detection by Western blot and proteins were visualized by chemiluminescence (Pierce). We used rabbit anti-human RSK4 (Abgent), anti-retinoblastoma (Rb)– associated 46 kDa (RbAptp46; Abcam) anti-CXCR4 (Santa Cruz), anti-cyclin E (Santa Cruz), anti-cyclin A (Santa Cruz), anti-Snail-2 (Santa Cruz), anti-E-cadherin (Santa Cruz), anti-MMP-2 (Santa Cruz) and anti-MMP-9 (Santa Cruz), p44/42 MAPK (Cell Signaling), phopho-p44/p42 (Thr202/Tyr204) MAPK (Cell Signaling) polyclonal antibodies; anti-p21 (Upstate), anti-pRb (Santa Cruz), anti-c-Myc (EMD), and anti-cyclin D1 (Santa Cruz) monoclonal antibodies; and goat anti-claudin-2 (CLDN2; Santa Cruz) antibody.

Immunostaining
Cells were cultured on coverslips for 24 h and then fixed with 10% formalin for 10 min, washed with PBS, and stored at 4°C. For staining, coverslips were treated with 0.5% Triton X-100 in PBS for 10 min and blocked for non-specific binding and endogenous peroxidase activity for 1 h at room temperature followed by incubation with primary antibody (anti-RSK4, rabbit polyclonal) at 37°C for 2 h in blocking buffer with 0.05% Triton X-100. After washing three times, cells were incubated with biotin-conjugated anti-rabbit antibody in the blocking buffer for 1 h at 37°C. After three washes, cells were incubated with streptavidin followed by washing three times, staining with 3,3-diaminobenzidine, and counterstaining with hematoxylin. Images were captured on a Zeiss microscope system.

3-(4,5-Dimethythiazol-2-yl)-2,5-diphenyltetrazoliumbromide assay
Cells were seeded in 96-well plate at 1,500 per 100 µL per well. Cells were grown in culture medium containing 10% FBS for 72, 96, and 120 h. At the end of incubation, 3-(4,5-dimethithiazol-2-yl)-2,5-diphenyltetrazoliumbromide (40 µL/well of 5 mg/mL 3-(4,5-dime-thythiazol-2-yl)-2,5-diphenyltetrazoliumbromide in PBS) was added to each well and plates were incubated in the dark for 3 h at 37°C. After removal of the medium, the dye crystals were dissolved in isopropanol and viable cells were detected by reading the absorption at 595 nm in the Ultra plate reader (Tecan Research). Experiments were repeated three times in quadruplicate wells to ensure the reproducibility of results.

Cell cycle analysis
Synchronized subconfluent vector control and RSK4-overexpressing cells cultured in the presence or absence of 5′-deoxy-5-fluorouridine (5′-dFUR) or low serum/serum deprived were harvested and washed twice with PBS. Pellets were resuspended in 0.5 mL PBS, fixed in 4.5 mL of 70% ethanol, and incubated overnight at -20°C. Cells were collected by centrifugation and washed once with PBS and the pellets were resuspended in 1 mL of 0.2 mg/mL propidium iodide containing 0.1% Triton X-100 (Sigma) and RNase A (1 mg/mL; Sigma). The cell suspension was incubated in the dark for 30 min at room temperature and subsequently analyzed on a Coulter EPICS 753 flow cytometer for DNA content. The percent of cells in different phases of the cell cycle was determined using a ModFit 5.2 computer program.

Small interfering RNA silencing of RSK4
Human RSK4-specific small interfering RNA (siRNA) were purchased from Ambion Biosciences. MDA-MB-231 cells (5 x 104 per well in six-well plate) were transfected with 200 pmol of the siRNA duplex for 48 h using Lipofectamine 2000 (Invitrogen). Transfection was done using lipofectamine. Transfected vector control and RSK4-overexpressing cells were transfected with either a scrambled sequence siRNA, which served as a negative control,
or siRNA against RSK4. Cells were harvested after 48 h and cell lysates were prepared to analyze the protein expression of RSK4 target proteins.

**In vitro assay for tumorigenesis**

Soft agar growth transformation assay. Anchorage-independent growth was assessed by colony formation on soft agar. Briefly, equal volumes of agar (1%, DNA grade) and 2 × DMEM (with 20% FBS) were mixed at 40°C to make 0.5% agar in six-well tissue culture plates (Corning) as a base agar. Cells (0.1 mL of 2.0 × 10⁶/mL) were suspended in 3 mL of 2 × DMEM (with 20% FBS) and 3 mL of 0.7% agar, and 1.5 mL cell suspension was then added to each well (as 0.35% top agar) with final concentration of 5,000 cells per well. Top agar was covered with culture medium. Plates were incubated at 37°C and 5% CO₂ in humidified incubator for 3 to 4 weeks and medium was covered with culture medium. Plates were incubated at 37°C and 5% CO₂ in humidified incubator for 3 to 4 weeks and medium was changed every 3 to 4 days. Colony formation was observed by light phase-contrast microscope and photomicrographed after staining with 0.5 mL of 0.01% crystal violet in PBS for 45 min at room temperature. Experiments were repeated twice to ensure the reproducibility of our results.

Matrigel invasion assay. The RSK4-overexpressing or vector control MDA-MB-231 cells were suspended at 1 × 10⁶/mL in medium containing DMEM/F-12 with 0.1% bovine serum albumin and 100 µL cell suspension was added to the upper well of Transwell inserts coated with 1 mg/mL Matrigel (BD Biosciences). In lower wells, 0.6 mL medium was added. The plates were incubated for 24 h at 37°C in 5% CO₂. After incubation, the inserts were carefully lifted and cells from the upper surface were gently removed and the remaining cells at the bottom side of the filter were fixed and stained using the Diff-Quick Staining. The results are expressed as the percentage of RSK4-overexpressing cells, which invaded the Matrigel and migrated to the bottom side of the Transwell membrane relative to the vector control cells. Each experiment was repeated at least three times in triplicates to ensure the reproducibility of our results.

Chemotaxis assay

Chemotaxis assay was done as described previously (18). Briefly, RSK4-overexpressing or vector control MDA-MB-231 cells were washed twice in serum-free medium (DMEM/F-12) containing 0.1% bovine serum albumin. For chemotaxis assay, 100 µL of 1 × 10⁶ cells/mL were added onto the upper well containing Transwell inserts with 8-mm pore size. In the lower well, either 0.6 mL medium containing CXCL12 (10 nmol/L) or vehicle was added. The plates were incubated for 6 h at 37°C in 5% CO₂. After incubation, the inserts were carefully lifted and cells from the upper surface were carefully removed, cells adhered on the top side of the membrane were scraped, and cells on the lower surface of the membrane were then stained using Diff-Quick staining and counted in at least five different fields. Each experiment was repeated at least three times in triplicates. Percentage chemotaxis in RSK4-overexpressing cells is relative to the number of cells that migrated in the presence of CXCL12 in vector control cells.

**In vivo tumorigenesis assay**

Six-week-old severe combined immunodeficient (SCID) mice were obtained from Taconic Farms. Mice were injected s.c. (n = 5 mice per clone) with 1 × 10⁶ cells resuspended in 0.1 mL DMEM without serum from two RSK4-overexpressing (MR11 and MR12) and two vector control (MN10 and MN11) clones. Tumor growth was monitored twice weekly. At the end of the monitoring period, animals were sacrificed by CO₂ asphyxiation, and tumor samples were removed and preserved in formalin. Thin sections were stained with H&E and examined by standard light microscopy.

**In vivo experimental metastasis**

For experimental lung metastasis, 1 × 10⁶ RSK4-overexpressing cells/mL (MR11 and MR12) or vector control cells (MN10 and MN11) in 100 µL DMEM (n = 5 mice/clones) were injected into the lateral tail veins of 6-week-old female SCID mice. At 10 weeks postinjection, lungs, liver, brain, kidney, and bones were harvested, fixed, and processed for histologic analyses.

RSK4 promoter-luciferase reporter construct and luciferase reporter assay

We cloned a regulatory region of the human RSK4 gene. A 640-bp nucleotide sequence was amplified by PCR using the following primers: 5′-ggaggactTCAGCTCTAGTTGCAAGGATG-3′ and 5′-cagctctagGCC- TAAAGTGACACAGCTA-3′. Forward primer contained XhoI restriction site and the reverse primer harbored a HindIII restriction site and a few additional nucleotides before the restriction sites. The PCR product was digested with XhoI and HindIII, cloned in TOPO vector (Invitrogen), and subcloned into the reporter vector pGL3-Basic (Promega) to generate a reporter construct. The construct was sequenced to check that no mutations were introduced during this process. For transfection, 200 ng pGL3 or putative RSK4 promoter-luciferase plasmid and combinations of various concentrations (0.5-3.0 µg) of c-Myc expression plasmid were used along with a β-galactosidase expression plasmid for normalization of transfection efficiencies. Luciferase and β-galactosidase activity was determined 48 h post-transfection using a luciferase reporter assay system (Promega). Luciferase units were calculated as luciferase activity/β-galactosidase activity and are presented as the mean ± SE of three individual experiments in triplicates. The fold change was calculated by comparison with the promoterless luciferase vector. HeLa cells were chosen for the transfection because these cells do not express endogenous RSK4.

**Statistical analysis**

All in vitro experiments were done in triplicate at least three times and in vivo experiments were done at least twice. Values are expressed as mean ± SE. Comparisons between groups were assessed with the Student’s t test. P values <0.05 were considered significant.

**Results**

Generation of RSK4-overexpressing stable clones. We used MDA-MB-231 cell line to overexpress RSK4 as it showed lower levels of endogenous RSK4 compared with other human breast cancer cell lines, which were screened for the expression of RSK4 and c-Myc (Fig. 1A, row 1). Stable clones of MDA-MB-231 cells overexpressing RSK4 were generated by transfection with a pcDNA3.1/neo-RSK4 plasmid or with pcDNA3.1/neo empty vector to establish control clones. Reverse transcription-PCR showed exogenous RSK4, identified by using the upstream primer located in the vector and downstream primer located in RSK4 insert, in several stable clones, whereas no specific product representing exogenous RSK4 mRNA was seen in the vector control clones (Fig. 1A, row 2, left). Typically, RSK4 clones showed ~2.5- to 3.5-fold higher RSK4 protein expression (Fig. 1A, row 2, right). Immunostaining showed both nuclear and cytoplasmic localizations of RSK4. Nuclear localization could be due to the presence of a nuclear localization signal in a loop within the NH₂-terminal kinase domain of RSK4 (13). A representative immunostaining in vector control-MN11 clone, RSK4-overexpressing-MR11 clone, and HeLa cells (negative control) is shown in (Fig. 1A, row 3). To confirm the nuclear localization of RSK4, we probed nuclear and cytoplasmic fractions for RSK4 proteins in vector control and RSK4-overexpressing clones. Representative data are shown in Fig. 1A (row 4).

RSK4-overexpressing cells show decreased cell proliferation and increased accumulation in G0-G1 phase. We used 3-(4,5-dimethylthiazol-2-)-2,5-diphenyltetrazolium bromide assay
to assess the cell proliferation of the RSK4 or empty vector-transfected stable clones by measuring the number of viable cells at different time points (72, 96, and 120 h). RSK4-expressing clones showed significantly decreased cell proliferation \((P < 0.05)\) at 120 h postseeding compared with vector control clones (Fig. 1B). The cell cycle distribution in RSK4-overexpressing and vector control cells was determined by fluorescence-activated cell sorting analysis under various serum conditions (10%, 5%, 2.5%, 1%, and 0% FBS) as well as after treatment with various concentrations \(5, 10, 20, \text{and} 30 \mu\text{mol/L}\) of 5\(\mu\)-dFUR. Under
serum-supplemented conditions, RSK4-overexpressing clones showed a significantly higher (10% FBS, \(P = 0.038\); 5% FBS, \(P = 0.042\)) percentage of cells accumulated in the G_0-G_1 phase compared with vector control clones. Treatment with 5’-dFUR resulted in significantly increased accumulation of cells in S phase with all three concentrations (10 μmol/L, \(P = 0.037\); 20 μmol/L, \(P = 0.029\); and 30 μmol/L, \(P = 0.022\)) tested in RSK4-overexpressing clones compared with vector control clones. Representative data at 96 h are shown in Table 1 with 10% or 0% FBS and 20 μmol/L 5’-dFUR in two RSK4-overexpressing clones (MR11 and MR12) and two vector control clones (MN10 and MN11).

**RSK4-overexpressing cells show increased expression of p21, pRb, and RbAp46 proteins.** Because RSK4-overexpressing clones showed increased accumulation of cells in G_0-G_1 phase, we then investigated the molecular targets involved in mediating this effect. We determined the expression pattern of proteins critical for G_1-S-phase transition. RSK4-overexpressing clones MR11 and MR12 showed increased levels of p21, hypophosphorylated pRb, and RbAp46 proteins, but no difference was observed for cyclin E, cyclin A, p44/42 MAPK, and phospho-p44/p42 (Thr202/Tyr204) MAPK proteins (Fig. 1C, left and bottom left). No difference was observed in the expression levels of Cdk2, Cdk4, and Cdk6 and Kip1/p27 between RSK4-overexpressing and vector control clones (data not shown). Surprisingly, MR11 and MR12 clones also showed increased levels of cyclin D1 compared with MN10 and MN11 vector control clones. Next, we determined the effect of serum starvation and treatment with 20 μmol/L 5’-dFUR on the expression of p21, pRb, RbAp46, and cyclin D1. Serum starvation resulted in reduced expression of RbAp46, whereas no changes were evidenced in either the phosphorylation status or the protein levels of p21, pRb, and cyclin D1 in RSK4-overexpressing cells. Treatment with 5’-dFUR induced phosphorylation of pRb, increased expression of RbAp46 and p21 proteins, and slightly decreased expression of cyclin D1 in RSK4-overexpressing cells (Fig. 1C, right). A previous study has already shown that RSK4 may regulate p21 (14). In this study, we assessed whether RSK4 contributes to the regulation of pRb, RbAp46, cyclin D1, and phospho-p44/p42 MAPK expression. RSK4-specific siRNA was used to silence the expression of RSK4 in two RSK4-overexpressing clones, MR11 and MR12. siRNA-mediated depletion of RSK4 showed reduction in pRb, RbAp46, and cyclin D1 protein levels, but no change was observed in phospho-p44/p42 (Thr202/Tyr204) MAPK protein compared with control siRNA-transfected cells (Fig. 1D).

**RSK4 can suppress the malignant phenotype of MDAMB-231 breast cancer cells.** We further investigated whether the RSK4-mediated effect on the cell cycle can influence the malignant phenotype of MDAMB-231 cells. We first assessed if RSK4 overexpression affects anchorage-independent growth and colony formation of MDAMB-231 cells in soft agar. A significant reduction (\(P < 0.0005\)) in colony formation was observed in RSK4-overexpressing MDAMB-231 cells manifested by both colony number and colony size compared with vector control clones (Fig. 2A). RSK4-overexpressing cells incubated for another 2 weeks did not show any increase in colony number or colony size. To rule out the possibility that this is not a cell-specific effect, we verified RSK4-mediated inhibition of colony formation in soft agar in RSK4-overexpressing T47D stable clones (TR1 and TR2) and vector control clones (TN1 and TN2). RSK4-overexpressing T47D clones also showed significantly lower colony formation (\(P < 0.0005\)) compared with vector control clones. Results are shown in Fig. 2B, which were consistent with RSK4-expressing MDAMB-231 cells.

Because MDAMB-231 is a highly invasive and metastatic cell line and RSK4 overexpression resulted in the suppression of soft agar colony formation by MDAMB-231 and T47D cells, we next tested whether RSK4 can affect the invasive and chemotactic ability of MDAMB-231 cells. RSK4-overexpressing clones were subjected to chemotaxis against CXCL12 and chemoinvasion on Matrigel containing CXCL12 recombinant protein. MR11 and MR12 (RSK4-overexpressing clones) clones showed a significantly reduced (\(P < 0.0001\)) chemotaxis against CXCL12 as well as a significantly reduced (\(P < 0.0001\)) chemoinvasion compared with vector control MN10 and MN11 clones (Fig. 2C and D).

**RSK4 inhibits chemotactic and invasive ability of MDAMB-231 cells by regulating the expression of CXCR4 and CLDN2 proteins.** To further explore the mechanism for the inhibition of invasion and migration, we determined the expression pattern of CXCR4, CLDN2, Snail-2, E-cadherin, MMP-2, and MMP-9 genes, which play roles in invasion and tissue-specific migration. RSK4-overexpressing clones showed reduced expression of CXCR4 and increased expression of CLDN2 proteins (Fig. 3A). No difference was observed in MMP-2 and MMP-9 protein expression levels or their activation status, and no detectable expression of E-cad was found in any of the samples (data not shown). Silencing of RSK4 expression using siRNA resulted in decreased expression of CLDN2 and increased expression of CXCR4 proteins (Fig. 3B). Furthermore, addition of a CXCR4 antibody in the upper wells with vector control clones (MN10 and MN11) showed ~40% to 50% reduction in chemotactic and chemoinvasive activities (Fig. 2C and D). These results indicate that suppression of invasion and directed migration of MDAMB-231 cells by RSK4 may be mediated through the regulation of CXCR4 and CLDN2 expression.

**In vivo suppression of tumor growth.** We next tested whether RSK4-overexpressing clones show difference in vivo tumorigenicity in SCID mice. RSK4-overexpressing (MR11 and

---

**Table 1. Cell cycle distribution of RSK4-overexpressing (MR11 and MR12) and vector control (MN10 and MN11) cells by fluorescence-activated cell sorting analysis**

<table>
<thead>
<tr>
<th></th>
<th>MR11</th>
<th>MR12</th>
<th>MN10</th>
<th>MN11</th>
</tr>
</thead>
<tbody>
<tr>
<td>10% FBS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G_0-G_1</td>
<td>80.0 ± 6.0*</td>
<td>86.0 ± 9.0*</td>
<td>68.0 ± 7.5</td>
<td>65.0 ± 5.0</td>
</tr>
<tr>
<td>G_2-M</td>
<td>8.0 ± 5.0</td>
<td>5.5 ± 1.5</td>
<td>18.0 ± 2.5</td>
<td>20.0 ± 2.5</td>
</tr>
<tr>
<td>S</td>
<td>12.0 ± 2.0</td>
<td>8.5 ± 2.5</td>
<td>14.0 ± 2.2</td>
<td>15.0 ± 4.5</td>
</tr>
<tr>
<td>0% FBS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G_0-G_1</td>
<td>74.5 ± 4.0</td>
<td>84.0 ± 6.0</td>
<td>71.0 ± 7.0</td>
<td>69.0 ± 7.0</td>
</tr>
<tr>
<td>G_2-M</td>
<td>8.0 ± 3.0</td>
<td>4.0 ± 2.5</td>
<td>16.5 ± 2.0</td>
<td>17.5 ± 3.0</td>
</tr>
<tr>
<td>S</td>
<td>17.5 ± 1.5</td>
<td>12.0 ± 3.0</td>
<td>12.5 ± 2.0</td>
<td>13.5 ± 3.0</td>
</tr>
<tr>
<td>5’-dFUR (20 μmol/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G_0-G_1</td>
<td>31.0 ± 6.0</td>
<td>57.0 ± 4.5</td>
<td>57.0 ± 4.5</td>
<td>52.0 ± 5.0</td>
</tr>
<tr>
<td>G_2-M</td>
<td>11.5 ± 3.0</td>
<td>0.0 ± 0.0</td>
<td>16.0 ± 2.0</td>
<td>19.5 ± 2.0</td>
</tr>
<tr>
<td>S</td>
<td>57.5 ± 2.0*</td>
<td>43.0 ± 6.0*</td>
<td>27.0 ± 3.0</td>
<td>28.5 ± 4.0</td>
</tr>
</tbody>
</table>

*\(P < 0.05\).
Fig. 2. RSK4 suppresses malignant phenotype of MDA-MB-231 breast cancer cells. A, crystal violet staining showing soft agar colony growth of RSK4 (MR11 and MR12) or empty vector (MN10 and MN11) transfected MDA-MB-231 stable clones. MR11 and MR12 clones showed significantly reduced \( P < 0.0001 \) or no growth in soft agar compared with an efficient anchorage-independent growth by vector control MN10 and MN11 clones in soft agar. Bottom, growth in soft agar by light phase-contrast microscopy (×50 magnification) of MR11, MR12, MN10, and MN11 seeded plates. B, significantly reduced \( P < 0.0003 \) soft agar colony growth of RSK4-transfected T47D stable (TR1 and TR2) compared with empty vector (TN1 and TN2) clones. Bottom, soft agar growth by light phase-contrast microscopy (×50 magnification). C, RSK4-transfected and vector control clones subjected to chemotactic assay in the presence of 10 nmol/L concentration of chemokine-CXCL12. MR11 and MR12 showed significantly reduced \( P < 0.00001 \) CXCL12-induced chemotaxis compared with vector control MN10 and MN11 cells (inset, ×50 magnification). Addition of anti-CXCR4 antibody in the upper wells with MN10 and MN11 showed ~50% reduced chemotaxis. D, RSK4-transfected clones analyzed for their chemoinvasive activity in a Matrigel invasion assay showed significantly reduced \( P < 0.0001 \) invasion compared with vector control cells (inset, ×50 magnification). Addition of anti-CXCR4 antibody in the upper wells with MN10 and MN11 showed ~40% reduced chemotaxis. All experiments were repeated at least three times and representative data are presented.

***, \( P < 0.0005 \).
MR12) and vector control (MN10 and MN11) cells were injected into the mammary fat pads of five female SCID mice and experiment was repeated at least twice. All mice (10 of 10) injected with MN10 and MN11-vector control cells developed palpable xenograft tumors at both left and right injection sites between 6 and 7 weeks; in MR11- and MR12-injected cells, 6 of 10 and 7 of 10 animals, respectively, formed tumors at 6 to 7 weeks postinjection. Mice injected with RSK4-overexpressing cells showed much smaller tumor size and significantly reduced ($P < 0.001$) tumor volume and weight compared with mice injected with vector control cells (Fig. 4A, top and middle). Histologic comparison of tumors showed penetrating growth in stromal tissue, indicating the highly invasive ability of tumors derived from vector control cells. On the other hand, tumors developed from RSK4-overexpressing clones showed a pseudocapsule, indicative of noninvasive growth. Representative photomicrographs are shown in Fig. 4A (bottom).

In vivo suppression of experimental metastasis. We used in vivo experimental model to determine whether RSK4-overexpressing MDA-MB-231 cells can suppress metastatic progression. We injected RSK4-overexpressing cells (MR11 and MR12) and vector control cells (MN10 and MN11) i.v. in SCID mice. In control group, metastasis developed in 80% of mice, whereas in mice injected with RSK4-overexpressing MDA-MB-231 cells metastasis was developed in 40% of mice. The number of gross metastatic lesions was noticeably declined in mice injected with RSK4-overexpressing cells compared with the control group. Representative examples of gross appearance of metastatic lesions in lungs of vector control-MN-10 (top left) and RSK4-overexpressing-MR11 (top right) injected clones are shown in Fig. 4B. Likewise, histologic examination of H&E-stained sections of lungs revealed numerous metastases in mice injected with vector control cells (Fig. 4B, middle and bottom left), whereas RSK4-overexpressing cells showed markedly decreased metastatic lesions (Fig. 4B, middle and bottom right). No metastatic lesions were detected in bones, liver, brain, or kidney either injected with RSK4-overexpressing cells or vector control cells.

RSK4 may be a transcriptional target of c-Myc. Because high expression of RSK4 was evident in the primary mammary tumors of MMTV-c-Myc transgenic mice by microarray analysis and quantitative reverse transcription-PCR (1), in this study, we further investigated whether c-Myc is likely to play a role in the regulation of RSK4. In agreement with our previous observation, MycER-overexpressing T47D cells showed upregulation of RSK4 (Fig. 5A) on conditional activation of c-MycER fusion protein (~97 kDa) with the selective estrogen receptor modulator 4-hydroxytamoxifen. Next, we investigated whether c-Myc can regulate RSK4 transcription. To address this question, we cloned a regulatory region of human RSK4 gene to investigate whether this region is regulated by c-Myc. The sequence analysis (using TF Bind software) revealed TATA and CAAT boxes and several other transcription factor binding sites including c-Myc consensus binding sequence (Fig. 5B). This fragment was then cloned into a pGL3 reporter vector. Overexpression of c-Myc in HeLa cells cotransfected with a luciferase reporter gene driven by RSK4 regulatory sequence (a putative RSK4 promoter) showed a dose-dependent induction of luciferase activity (Fig. 5C), thereby suggesting that c-Myc may regulate RSK4 through specific binding to a regulatory region of the RSK4 gene.

Discussion

This study shows that 90-kDa RSK4 can suppress the tumor growth and the invasive and metastatic ability of MDA-MB-231 breast cancer cells. We measured these phenotypic changes in vitro artificial extracellular matrix (Matrigel) in vitro and (b) grow noninvasive tumors in SCID mice and reduced metastatic lesion in lungs after i.v. injected RSK4-overexpressing cells in SCID mice in vivo. Results of these experiments indicate that increased expression of RSK4 protein can impair the malignant properties of MDA-MB-231 cells. To exclude the possibility that tumor size may contribute to invasion of surrounding tissues, mice injected with RSK4-overexpressing cells were kept for additional 4 weeks to see whether observed tumor size is due to slow-growing properties of these cells and whether increase in size will affect the invasive properties of RSK4-overexpressing cells. Even after 4 weeks, tumors did not grow significantly as well as the tumor morphology and edge was confined (data not shown).

Intriguingly, RSK4-overexpressing cells showed decreased expression of CXCR4 and increased expression of CLDN2 and vice versa after silencing of RSK4. Both of these factors have been shown to play roles in invasion and chemotaxis. Chemotaxis is critical for preferential homing of cancer cells
to metastatic sites. In particular, up-regulation of CXCR4 on cancer cells and CXCR4/CXCL12-induced motility have been implicated in the metastasis of breast cancer in lymph nodes, lungs, and bones (19–21). Similarly, CLDN2, a transmembrane protein, is an essential component of tight junction strands that contribute to the maintenance of epithelial tissue integrity (22–24). Alteration in tight junction barrier function can result in epithelial to mesenchymal transition; therefore, down-regulation of any of the tight junction components consequently can cause cells to adopt a migratory behavior. Loss or reduced expression of claudins has been implicated in epithelial to mesenchymal transition and metastasis (25, 26).

Fig. 4. A, tumor formation by RSK4-overexpressing or vector control MDA-MB-231 cells in SCID mice. SCID mice were inoculated s.c. with $10^6$ cells from MR11, MR12, MN10, and MN11 clones; mice ($n = 5 \times 2$) were monitored twice weekly for the evidence of tumor growth. Top, gross appearance of tumors formed by vector control (MN11) or RSK4-overexpressing (MR11) MDA-MB-231 cells at 6 to 7 wk postinjection; middle, average ± SE tumor weight and tumor volume from each group; bottom, representative histologic appearance of tumors formed by vector control or RSK4-overexpressing MDA-MB-231 cells. **, $P < 0.005$. B, experimental metastasis. Top left, gross examination of lungs from mice injected with vector control cells (MN10) showed numerous surface metastatic lesions (arrows); middle and bottom left, histologic examination revealing multiple metastases (arrows) in vector control cells (MN11) injected mice (middle left, low magnification; bottom left, high magnification); top right, mice injected with RSK4-overexpressing cells (MR11) revealed fewer surface lesions; middle and bottom right, histologic evaluation also showed much fewer metastatic lesions (middle right, low magnification; bottom right, high magnification) in the lungs of mice injected with RSK4-overexpressing cells (MR11).
Antibody-mediated inhibition of CLDN2 resulted in enhanced invasive activity (data not shown), whereas antibody-mediated inhibition of CXCR4 showed ~50% reduced chemotactic activity. These data suggest that RSK4-regulated CLDN2 and CXCR4, in part, may abrogate the invasive and migratory phenotype of MDA-MB-231 cells.

Overexpression of RSK4 results in decreased cell proliferation and significantly increased accumulation of cells in the G0-G1 phase of the cell cycle, whereas robust S-phase accumulation was observed on treatment with 5′-dFUR. Significantly increased accumulation of cells in the G0-G1 phase is in concurrence with a previous study where depletion of RSK4 abrogated the p53-dependent G1 cell cycle arrest (14). RSK4-overexpressing clones show predominantly hypophosphorylated Rb protein and increased expression of p21 protein under normal serum conditions (10% FBS), which may be responsible for the increased accumulation of RSK4-overexpressing cells in the G1 phase. It is known that hypophosphorylation of pRb and increased expression of p21 can arrest cells in the G1 phase (27, 28). The precise molecular mechanism by which RSK4 drives cells into S phase on treatment is unclear. Phosphorylation of pRb is known to be responsible for G1-S-phase progression (29). It is likely that phosphorylation of pRb on treatment in RSK4-overexpressing clones may drive these cells into S phase.

Interestingly, RSK4-overexpressing clones also showed marked induction of RbAp46; however, it is yet to be determined whether RbAp46 also contributes to G0-G1 under various serum conditions or S-phase accumulation after treatment with 5′-dFUR. RbAp48/RbAp46 physically associates with E2F1 in the presence of Rb and histone deacetylase (30) to repress transcription of E2F-responsive genes; thus, increased expression of RbAp46 is likely to arrest cells in G1 phase. We also found high expression of cyclin D1 in RSK4-overexpressing cells. Overexpression of cyclin D1 occurs frequently in several types of human cancer and plays diverse roles contingent on its expression level, cell type, and cell context. Various studies have shown that overexpression of cyclin D1 can promote cell proliferation and enhance tumorigenesis (31, 32). On the other hand, many studies have shown that cyclin D1 can inhibit cell cycle progression, arrests cells either in G0-G1, or S phase, and induces apoptosis in response to various stimuli (33–35). It is likely that RSK4-induced increased expression of cyclin D1 contributes to RSK4-mediated cell cycle arrest.

RSK4 maps to chromosome Xq21, a region where deletions have been shown in various cancer patients (36–38). We have also recently shown the loss of expression or reduced expression of RSK4 mRNA in >50% of human breast cancer cases compared with adjacent normal tissues (16). Many studies have reported 14% to 30% loss of Xq region in primary breast carcinomas and infiltrative ductal or lobular carcinomas (38–40). Whether expression patterns of RSK4 can predict the predisposition of breast tumors for invasion and metastasis needs further investigations.

Finally, we show marked induction of endogenous RSK4 and increased luciferase reporter gene activity (−640-bp regulatory region of RSK4-pGL3) in c-Myc-overexpressing cells. These data suggest that RSK4 expression may be regulated by c-Myc. We have shown previously up-regulation of RSK4 in the mammary tumors of MMTV-c-Myc transgenic mice compared with normal mammary glands and mammary tumors of MT-TGFβ transgenic mice (1). Consistent with our findings that RSK4 is able to inhibit invasion and metastasis of breast cancer cells, mammary tumors of MMTV-c-Myc transgenic mice are also noninvasive and nonmetastatic. Based on these data, we speculate that the noninvasive and nonmetastatic phenotype of mammary tumors from MMTV-c-Myc transgenic mice, in part, could be due to c-Myc-induced expression of RSK4.

In summary, we have shown that RSK4 may play a critical role in breast cancer invasion. RSK4 being a ribosomal protein kinase may not only play a role in the regulation of gene expression through post-translational modifications but also through transcriptional and post-transcriptional modifications of transcription factors, coregulators, and other unknown target proteins. How RSK4 can suppress transformation, invasion, and metastasis warrants further investigations. Understanding of mechanism(s) of how RSK4 regulates these phenotypes may allow manipulation of RSK4-mediated signaling and to design a new therapeutic strategy.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.


Clark DE, Poteet-Smith CE, Smith JA, Lannigan DA. Rsk2 allosterically activates estrogen receptor α by docking to the hormone-binding domain. EMBO J 2001;20:2484–94.


Anti-invasive and Antimetastatic Activities of Ribosomal Protein S6 Kinase 4 in Breast Cancer Cells

Archana Thakur, Yuan Sun, Aliccia Bollig, et al.